Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms.

Amer M ZeidanKate PerepezkoTehseen SalimiTerri WashingtonRobert S Epstein

Published in: Therapeutic advances in hematology (2024)

Survey results suggest very little/no impact on regular daily activities and improved QOL with oral DEC-C relative to IV/SC HMAs, highlighting the potential for oral DEC-C to reduce the treatment burden associated with parenteral HMA therapy.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
stem cells
peritoneal dialysis
risk assessment
replacement therapy
human health